Leyden Laboratories Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer

Thursday, 12 September 2024, 05:51

Leyden Laboratories announces the appointment of Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer. Dr. Ananworanich, with extensive experience in infectious disease, previously led influenza vaccine development at Moderna. His expertise aligns perfectly with Leyden Labs' mission to innovate in medical solutions.
LivaRava_Medicine_Default.png
Leyden Laboratories Appoints Jintanat Ananworanich, M.D., Ph.D., as Chief Medical Officer

Key Appointment at Leyden Laboratories

Leyden Laboratories B.V. has officially appointed Jintanat Ananworanich, M.D., Ph.D., as the new Chief Medical Officer. Dr. Ananworanich's impressive track record includes leading the development of influenza vaccines at Moderna, positioning him as a significant asset to Leyden Labs.

About Dr. Ananworanich

With over 20 years of clinical and industry experience in infectious disease, Dr. Ananworanich brings a wealth of knowledge to his new role. His commitment to advancing medical technology and innovation aligns with Leyden Labs’ goals.

The Future of Leyden Laboratories

As Leyden Laboratories continues to grow, the appointment of Dr. Ananworanich marks a key step in enhancing the company’s leadership in the medical field. This strategic move is aimed at bolstering their research and development efforts.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe